pp-063 Solution for infusion

"Indication: Solid tumors and neurological conditions associated with xCT-dependent metabolic vulnerability, including newly diagnosed metastatic colorectal cancer (mCRC) in combination therapy, pediatric DIPG/DMG (diffuse glioma types) with radiation, and chemotherapy-induced peripheral neuropathy (CIPN) under monotherapy evaluation. Clinical stage: Phase 2 clinical development across oncology and neurology programs, including combination therapy for mCRC and DIPG/DMG, and monotherapy proof-of-concept studies for CIPN. Modality: Biologic therapeutic (protein/peptide-based) Mechanism / Target: Modulates the xCT (SLC7A11) cystine/glutamate antiporter, disrupting cystine uptake and glutathione production to induce oxidative stress and ferroptotic death in xCT-dependent tumor cells while supporting targeted metabolic effects in neural tissues. Route / form: Intravenous infusion Differentiation: First-in-class xCT-modulating therapeutic advancing in both high-need oncology indications and non-oncology neuropathy; demonstrates versatility in combination regimens for aggressive tumors and meaningful potential in monotherapy for CIPN, expanding its partnering and clinical value.